High-Cost Prescription Drugs

• On February 10, 2020, the legislature enacted HB 703 relative to new high-cost prescription drugs. The law requires a prescription drug manufacturer to notify the Insurance Department “if it is introducing a new prescription drug to market at a wholesale acquisition cost that exceeds the threshold set for a specialty drug under the Medicare Part D program.” RSA 318:68, I.
• Bulletin: HB 703, New High-Prescription Drugs

Information must be submitted to the Department using the following template:

• High-Cost Prescription Drug File Template

New High Cost Drugs Introduced in New Hampshire

Prescription drug manufacturers are required by New Hampshire law to provide certain notice to the Insurance Department if they are introducing a new prescription drug to market at a wholesale acquisition cost that exceeds the threshold set for a specialty drug under the Medicare Part D program (House Bill 703, NH RSA 318:67-68, III).

For prior high-cost drug reports please click here